论文部分内容阅读
目的:研究Galectin 3、CD44v6在滤泡上皮起源甲状腺肿瘤中表达及其意义。方法:应用Envision二步免疫组织化学方法检测Galectin 3、CD44v6在30例甲状腺乳头状癌、11例甲状腺滤泡癌、3例甲状腺未分化癌及9例甲状腺滤泡腺瘤中的表达。甲状腺肿瘤旁甲状腺组织作为阴性对照组。结果:Galectin-3在乳头状癌、滤泡癌、未分化癌及滤泡腺瘤各组中的阳性表达率分别为100.00%(30/30)、100.00%(11/11)、100.00%(3/3)、33.33%(3/9),各组与对照组的阳性表达(100%)差异有统计学意义(P<0.01)。CD44v6阳性表达率分别为90.00%(27/30)、81.81%(9/11)、66.67%(2/3)、66.67%(6/9),各组与对照组的阳性表达(100%)差异有统计学意义(P<0.01)。Galectin-3与CD44v6在甲状腺乳头状癌中的表达呈正相关(r=0.69,P<0.05)。在甲状腺滤泡癌中的表达也呈正相关(r=0.63,P<0.05)。结论:联合检测Galectin-3、CD44v6可能是滤泡上皮起源甲状腺肿瘤病理鉴别诊断及临床预后的重要生物学标记物。
Objective: To investigate the expression and significance of Galectin 3 and CD44v6 in follicular epithelial derived thyroid tumors. Methods: The expressions of Galectin 3 and CD44v6 in 30 cases of thyroid papillary carcinoma, 11 cases of thyroid follicular carcinoma, 3 cases of thyroid undifferentiated carcinoma and 9 cases of thyroid follicular adenoma were detected by Envision immunohistochemistry. Thyroid tumor parathyroid tissue as a negative control group. Results: The positive rates of Galectin-3 in all groups of papillary carcinoma, follicular carcinoma, undifferentiated carcinoma and follicular adenoma were 100.00% (30/30), 100.00% (11/11), 100.00% ( 3/3) and 33.33% (3/9) respectively. There was significant difference (P <0.01) between the positive expression and the control group (100%). The positive rates of CD44v6 expression were 90.00% (27/30), 81.81% (9/11), 66.67% (2/3) and 66.67% (6/9) The difference was statistically significant (P <0.01). The expression of Galectin-3 and CD44v6 in papillary thyroid carcinoma was positively correlated (r = 0.69, P <0.05). The expression of thyroid follicular carcinoma was also positively correlated (r = 0.63, P <0.05). Conclusion: The combined detection of Galectin-3 and CD44v6 may be important biomarkers for differential diagnosis and clinical prognosis of thyroid tumors with follicular epithelial origin.